本文仅供中国大陆地区执业的医学药学专业人士参考，如您非前述专业人士，请离开本页面
✩ 本文仅供医疗卫生等专业人士参考
审批编码：PP-IX-CN-4513
获批日期：2024 年 9 月 14 日
内容策划：韩雪珂
项目审核：曹欢
题图来源：礼医提供
参考文献
[1] van der Heijde D, et al. J Rheumatol. 2022;49(3):265-273.
[2] Maksymowych WP, et al. Effect of Ixekizumab Treatment on MRI Structural Lesions in the Sacroiliac Joints of Patients With Radiographic Axial Spondyloarthritis; A Post Hoc Analysis of a Placebo and Active Controlled RCT. 2023 ACR.
[3] van der Heijde D, et al. Lancet. 2018;392:2441-51.
[4] Mease P, et al. Rheumatol Ther.2019;6:435-50.
[5] Deodhar AA, et al. BMC Rheumatol. 2021;5(1):35.
[6] Xue Y, et al. BioDrugs. 2023 Sep 22. doi: 10.1007/s40259-023-00625-2. Online ahead of print.
[7] K. de Vlam, et al. Ixekizumab Shows a Distinct Pattern of Pain Improvement Beyond Measurable Inflammation as Assessed by MRI or CRP or BASDAI Questions 5 & 6 in Patients with Ankylosing Spondylitis. ACR Convergence 2021. Abstract Number: 0919.
[8] Genovese MC, et al. N Engl J Med 2016;374:1243-52.
[9] Takeuchi T, et al. Ann Rheum Dis. 2019;78:171–178.
[10] Takeuchi T, et al. Ann Rheum Dis. 2019;78:171–178 supplementary appendix.
[11] Magrey MN, et al. Mayo Clin Proc. 2020;95(11):2499-2508.
[12] Caetano AP, et al. Front Med(Lausanne). 2021;8:658538.
[13] 王炎焱,等. 中华内科杂志,2021,60(3):187-191.
[14] Maksymowych WP, et al. Ann Rheum Dis. 2019; Nov;78(11):1550-1558.
[15] Di Dier K, et al. Best Pract Res Clin Rheumatol. 2023 Sep;37(3):101876.
[16] 徐胜前,等.中华内科杂志.2019;58(10):705-708.
[17] 中国医师协会风湿免疫科医师分会影像学组, 等.中华风湿病学杂志, 2021,25(9): 577-583.
[18] Mauro D, et al. Rheumatol Ther. 2024 Feb;11(1):19-34.
[19] Dinneen B, et al. Best Pract Res Clin Rheumatol. 2023 Sep;37(3):101898.
[20] Zhang JR, et al. Front Med(Lausanne). 2019;6:214.
[21] Venetsanopoulou AI, et al. Rheumatol Int. 2024 Jan 31.
[22] Deodhar A, et al.J Rheumatol. 2023,50(8):1020-1028.
[23] McGonagle DG, et al. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019 Sep;78(9):1167-1178.
[24] Ramiro S, et al. Ann Rheum Dis. 2023;82(1):19-34.
[25] Strand V, et al. J Clin Rheumatol. 2021;27(8):e446-e455.
[26] Luo H, et al. Cell Rep 2019;29:2384-2397.e5.
[27] Callis Duffin K, et al. Med Devices (Auckl). 2016;9 361-369.
[28] 依奇珠单抗注射液说明书.
[29] Tan Y, et al. RMD Open. 2022;8(2):e002387.
[30] Smolen JS. Nat Rev Rheumatol 2015;11:276-289.
[31] Genovese MC,et al. 2015 ACR. Previous Biologic Disease-Modifying Antirheumatic Drug Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors.
[32] Caporali R, et al. Poster presented at EULAR 2022. POS0682.
[33] Miyazaki Y, et al. Ann Rheum Dis. 2021;80(9):1130-1136.
[34] Gremese E, et al. Ann Rheum Dis. 2013 Jun;72(6):858-62.
[35] Schipper LG, et al. Arthritis Res Ther. 2010;12(3):R97.
[36] Finckh A, et al. Arthritis Rheum 2006;55:864-72.
[37] 中华医学会风湿病学分会. 中华内科杂志, 2018, 57(4):10.
[38] Smolen JS, et al. Ann Rheum Dis 2020;0:1–15.
[39] 耿研,等. 中华内科杂志, 2022, 61(1): 51-59.
[40] Taylor PC, et al. Ann Rheum Dis. 2022 Mar;81(3):335-343.
[41] Wu CY, et al. AB0455. Annals of the Rheumatic Diseases 2023;82:1418.
[42] 巴瑞替尼片说明书.
